Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ORRIN M TROUM

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1821032608
CMS profile
354633
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$264,805.57

452 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 10; records 151–200 of 452 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ORRIN M TROUM

NPI 1821032608 · CMS profile ID 354633

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 10; records 151–200 of 452 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821032608?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ORRIN M TROUM, NPI 1821032608, CMS profile ID 354633. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 452 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821032608?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ORRIN M TROUM, NPI 1821032608, CMS profile ID 354633. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 452 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821032608?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ORRIN M TROUM, NPI 1821032608, CMS profile ID 354633, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 10; records 151–200 of 452 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1821032608?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

452 matching records · $264,805.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 452 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 452.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $3,850.0009/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704586 CMS
Amgen Inc. $2,750.0009/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704588 CMS
AstraZeneca Pharmaceuticals LP $127.9409/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104713309 CMS
SCILEX PHARMACEUTICALS INC. $24.4709/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136271201 CMS
Novartis Pharmaceuticals Corporation $29.8409/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087345920 CMS
PFIZER INC. $5.4409/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131844070 CMS
PFIZER INC. $30.4109/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131880555 CMS
PFIZER INC. $1.7309/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131888065 CMS
Radius Health, Inc. $22.1609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089981295 CMS
Amgen Inc. $41.4009/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704580 CMS
AstraZeneca Pharmaceuticals LP $45.1009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105590662 CMS
Amgen Inc. $86.3409/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116185008 CMS
AstraZeneca Pharmaceuticals LP $23.9209/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105628281 CMS
GlaxoSmithKline, LLC. $16.9709/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116443247 CMS
ABBVIE INC. $8.8608/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246088 CMS
Kiniksa Pharmaceuticals International, plc $20.5708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154859006 CMS
Janssen Biotech, Inc. $142.5408/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078340252 CMS
UCB, Inc. $35.1708/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143088464 CMS
Novartis Pharmaceuticals Corporation $7.2008/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087345918 CMS
Janssen Biotech, Inc. $22.4708/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078340500 CMS
Amgen Inc. $19.4908/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116184982 CMS
Amgen Inc. $550.0008/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704550 CMS
Radius Health, Inc. $25.4508/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089981289 CMS
ABBVIE INC. $10.5508/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246086 CMS
Amgen Inc. $15.0008/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116184855 CMS
ABBVIE INC. $3,500.0008/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246084 CMS
Bioventus LLC $20.4308/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137450755 CMS
ABBVIE INC. $5,600.0008/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246082 CMS
ABBVIE INC. $124.9908/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246080 CMS
Amgen Inc. $17.5708/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116184774 CMS
Amgen Inc. $9.0608/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704572 CMS
Novartis Pharmaceuticals Corporation $25.3808/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087345912 CMS
AstraZeneca Pharmaceuticals LP $110.6308/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105205100 CMS
Lilly USA, LLC $1,400.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135255561 CMS
SCILEX PHARMACEUTICALS INC. $20.3708/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136263922 CMS
ABBVIE INC. $28.1908/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246078 CMS
Lilly USA, LLC $1,400.0008/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135302388 CMS
Amgen Inc. $29.6908/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116184850 CMS
Amgen Inc. $2,475.0008/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117704576 CMS
Lilly USA, LLC $1,400.0008/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135272789 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.4408/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118166926 CMS
Janssen Biotech, Inc. $5.7408/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078339434 CMS
Janssen Biotech, Inc. $5.7208/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078339665 CMS
ABBVIE INC. $700.0008/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246074 CMS
ABBVIE INC. $3,500.0008/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106246076 CMS
Lilly USA, LLC $32.8208/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135302392 CMS
Genentech USA, Inc. $21.1808/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133084201 CMS
PFIZER INC. $3.4108/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131768387 CMS
PFIZER INC. $33.8008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131774519 CMS
Amgen Inc. $25.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116184990 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $344,034.53 708
PY2020 $169,225.49 374
PY2021 $142,007.43 411
PY2022 $272,100.45 584
PY2023 $250,359.35 465
PY2024 $264,805.57 452
PY2025 $322,150.19 533

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,440.00 1
PY2025 Principal investigator $1,609,916.63 32
PY2024 Principal investigator $1,165,863.00 22
PY2023 Principal investigator $792,698.43 9
PY2022 Principal investigator $863,292.36 7
PY2021 Principal investigator $478,805.47 6
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $172,530.47 21
PY2019 Principal investigator $17,337.29 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $15,640.00 12/22/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381012
Principal investigator 1 UCB SA $5,077.00 12/08/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246656800
Principal investigator 1 Janssen Research & Development, LLC $16,893.00 11/28/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381040
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
ORRIN TROUM MD AND MEDICAL ASSOCIATES
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190306413
Principal investigator 1 ABBVIE INC. $17,096.00 11/04/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520779
Principal investigator 1 Janssen Research & Development, LLC $30,192.00 10/30/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381003
Principal investigator 1 Janssen Research & Development, LLC $33,156.00 09/29/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN CALIFORNIA
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381018
Principal investigator 1 Amgen Inc. $10,166.67 09/24/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
P4 Uncontrolled Gout AGILE No dispute reported 06/30/2026 1246650789
Principal investigator 1 Janssen Research & Development, LLC $36,984.00 08/28/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN CALIFORNIA
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381035
Principal investigator 1 Amgen Inc. $49.98 08/26/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOHN'S HEALTH CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646924
Principal investigator 1 Amgen Inc. $58,699.68 07/11/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246646897
Principal investigator 1 UCB SA $50,207.00 07/11/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657842
Principal investigator 1 ABBVIE INC. $23,334.00 07/02/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494987
Principal investigator 1 SANOFI US SERVICES INC. $2,800.00 07/02/2025 Non-covered Recipient Entity
Providence Health System Southern C
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226087234
Principal investigator 1 SANOFI US SERVICES INC. $13,675.00 07/02/2025 Non-covered Recipient Entity
Providence Health System Southern C
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226087238
Principal investigator 1 Janssen Research & Development, LLC $29,090.00 06/19/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN CALIFORNIA
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175381026
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,200.00 05/22/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190304819
Principal investigator 1 ABBVIE INC. $13,528.00 05/15/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485207
Principal investigator 1 SANOFI US SERVICES INC. $2,800.00 05/12/2025 Non-covered Recipient Entity
Providence Health System Southern California Dba P
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226151954
Principal investigator 1 SANOFI US SERVICES INC. $13,675.00 04/14/2025 Non-covered Recipient Entity
Providence Health System Southern California Dba P
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226151949
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,700.00 04/08/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190305249
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,315.77 04/08/2025 Non-covered Recipient Entity
ORRIN TROUM MD AND MEDICAL ASSOCIATES
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190306417
Principal investigator 1 ABBVIE INC. $6,492.00 04/03/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202469347
Principal investigator 1 ABBVIE INC. $22,876.00 03/07/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460551
Principal investigator 1 Amgen Inc. $24,081.00 02/11/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOHN'S HEALTHCENTER
P4 Uncontrolled Gout AGILE No dispute reported 06/30/2026 1246646928
Principal investigator 1 ABBVIE INC. $6,764.00 02/06/2025 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM - SOUTHERN
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202447337
Principal investigator 1 Amgen Inc. $579,793.36 02/03/2025 Non-covered Recipient Entity
SAINT JOHN'S HEALTH CENTER - PROVIDENCE ST JOHN'S HEALTH CTR
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246647538
Principal investigator 1 Novartis Pharmaceuticals Corporation $64,295.36 01/28/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190305251
Principal investigator 1 UCB SA $1,110.26 01/23/2025 Non-covered Recipient Entity
The Doctors Of Saint Johns Rheumatology
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657498
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $208,872.80 01/21/2025 Non-covered Recipient Entity
Providence St. John's Health Center
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235994437
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $108,197.91 01/21/2025 Non-covered Recipient Entity
Providence Saint Johns Medical Foundation
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235994441
Principal investigator 1 Novartis Pharmaceuticals Corporation $110,137.72 01/15/2025 Non-covered Recipient Entity
ORRIN TROUM MD AND MEDICAL ASSOCIATES
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190306415
Recipient Amgen Inc. $1,440.00 01/12/2025 Covered Recipient Physician Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events were Infrequent During Clinical Trials of Pegloticase No dispute reported 06/30/2026 1246637212